Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide. - Wikidata - awgldk - TriplyDB

Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.

Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.

http://www.wikidata.org/entity/Q36976659

about

Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers Microbicides: topical prevention against HIV Elucidating a key anti-HIV-1 and cancer-associated axis: the structure of CCL5 (Rantes) in complex with CCR5.Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES A novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitro Peptide and protein-based inhibitors of HIV-1 co-receptors Emerging concepts and approaches for chemokine-receptor drug discovery.Chemokine receptor oligomerization and allostery.Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry."Resistance" to PSC-RANTES revisited: two mutations in human immunodeficiency virus type 1 HIV-1 SF162 or simian-human immunodeficiency virus SHIV SF162-p3 do not confer resistance.Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.Phages and HIV-1: from display to interplay.CC chemokine receptor 5 (CCR5) desensitization: cycling receptors accumulate in the trans-Golgi network.Constitutively active CCR5 chemokine receptors differ in mediating HIV envelope-dependent fusion.Natural anti-CCR5 antibodies in HIV-infection and -exposure CCR5 conformations are dynamic and modulated by localization, trafficking and G protein association Highly potent chimeric inhibitors targeting two steps of HIV cell entry Discovery of modulators of HIV-1 infection from the human peptidome.CCR5: From Natural Resistance to a New Anti-HIV Strategy.Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).Chemokine and chemokine receptor structure and interactions: implications for therapeutic strategies.Conformational dynamics of single G protein-coupled receptors in solution Potent Anti-HIV Chemokine Analogs Direct Post-Endocytic Sorting of CCR5 Dual targeting of the chemokine receptors CXCR4 and ACKR3 with novel engineered chemokines.Structural Determinants for the Selective Anti-HIV-1 Activity of the All-β Alternative Conformer of XCL1.CCR5 susceptibility to ligand-mediated down-modulation differs between human T lymphocytes and myeloid cells.CCR5 mutations distinguish N-terminal modifications of RANTES (CCL5) with agonist versus antagonist activity.The role of individual carbohydrate-binding sites in the function of the potent anti-HIV lectin griffithsin.A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris.Topically applied recombinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors.HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection.Role of CXCR4 internalization in the anti-HIV activity of stromal cell-derived factor-1α probed by a novel synthetically and modularly modified-chemokine analog.Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches Characterization of structure, dynamics, and detergent interactions of the anti-HIV chemokine variant 5P12-RANTES.Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention.Biology and clinical relevance of chemokines and chemokine receptors CXCR4 and CCR5 in human diseases.Chemokine oligomerization in cell signaling and migration.Long synthetic peptides for the production of vaccines and drugs: a technological platform coming of age.

P2860

Q24620129-2476027A-E3E3-4F83-B912-2214853A1926 Q26999403-A738F928-3F44-4642-A6B9-2C476223749A Q27309182-7855A9B1-01ED-4856-9278-8F4D3BE5C281 Q27657257-83A62FA8-C071-4903-ABDA-518C0EF28039 Q28728917-98F021FA-85A0-4904-8948-6668CE902DAC Q30352117-BDC76A07-085A-4128-8753-EB2E2F91560C Q33763369-5D5497E6-98A7-4B8C-B21D-AF27A5C3DE1B Q33810517-8EC8BC2D-C933-49DB-964B-78E054CA24D1 Q33846502-866ADB4E-78C3-4C1B-BE57-21D4ADFE9995 Q33877312-05C6FB01-FB46-47FA-BE2B-CBB43F5E6BAB Q33961704-DFCBD272-5FBA-4DD3-A11A-C31D77DB33D8 Q34273397-8BF17629-6201-482A-89D2-5625F996CF31 Q34438951-46359FF8-8CA6-40FC-87F6-6E7A27C58C46 Q34565057-FA5E1B1C-8D59-43DB-ADB1-9C0F8E4F5A46 Q35018133-4903C4C8-3D61-469E-890C-FA275FBB190D Q35106596-AA58FE69-66B7-48A8-82F6-5122C9A6728A Q35150195-1899B2AF-E385-440C-A08B-270D25B3D0C1 Q35222585-6BDECB6B-F72C-4BD1-B133-CBE835ED24B0 Q35260605-567A2BD8-0E19-41C9-8E2C-952C8312E255 Q35312348-1647AA52-B712-47ED-85E4-9DEE09B7935C Q35528569-6A5976FE-755C-408E-A6DC-7A6A1EB586F0 Q35541732-38567170-7A5E-4D50-B49B-CEB32DE8C061 Q35617641-99FD4080-BE6B-4CA0-B39D-C1CDB534FD28 Q35718010-A2795037-E244-4D3B-B27E-F3F5B2A5106D Q35913867-A2160147-CBD1-44B0-8A53-322E3C38CEE6 Q36028163-47ACD3FF-8CDB-49BF-8E08-9743EDAB7357 Q36246273-C6BCB2D7-3BC9-44DF-A5F0-673264A590EC Q36327928-3D02923E-91C1-43EA-9C99-D943F042C104 Q36498554-6AC49C96-6A9B-4B4A-B3E0-9D49AE2A2171 Q36765045-E4542156-B211-40CB-AB54-780473CE2650 Q36827348-5FE744ED-7769-45AF-AEAD-15AED87B1CEA Q36915528-EC653156-A55E-422E-8407-D92D22DCFFCC Q37088591-5A7F05B4-DA6F-42FF-8858-DC3CC6C18ED4 Q37118537-4714CDCD-13FE-4D5E-B052-A669D462340C Q37252004-FD54AFB4-7298-4F2F-B84A-48062681E2DD Q37368217-AE3E1522-D6FC-4A49-AD1D-34BA99F26193 Q37458024-2731FAFF-A3AF-4CD9-AF5A-587926091B2B Q37599363-CB2CF734-CC10-4D0D-87A2-BD81B0B32784 Q37608845-C6ACE9EA-51FE-4756-ABE9-0BA565A0EB9F Q37791308-C984875B-3A25-45D0-8137-2C7957CA9A15

P2860

Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.

http://www.wikidata.org/entity/Q36976659

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Highly potent, fully recombina ...... eering a low-cost microbicide.

@en

type

label

Highly potent, fully recombina ...... eering a low-cost microbicide.

@en

prefLabel

Highly potent, fully recombina ...... eering a low-cost microbicide.

@en

P1433

Q36976659-6A47E583-0878-4617-88AF-2E03E859B427

P1476

Q36976659-ABD75737-68CA-4709-BBB8-27C9897F71D2

P2093

Q36976659-002A29B6-2273-41B2-83CB-3E814AF80806

Q36976659-04250E6F-5B9D-4904-8C84-31A8A7C0D165

Q36976659-09A83D1F-CA61-49BE-A68E-45D8D26829EB

Q36976659-10BC158D-BDE4-415D-8F3E-863889936247

Q36976659-16708F93-1196-42F1-A294-C2EFA40D0614

Q36976659-4D81A10F-B09B-46A6-B4E7-3FD162E45824

Q36976659-59EFB99F-35EB-4596-BDD5-50F6390E3617

Q36976659-68108DF2-E60B-49F2-914B-F482389EED5E

Q36976659-B1A47333-1A35-4F2E-BAFA-4BCFDC875346

Q36976659-E42DD16E-AAAF-4413-A7E3-FB03D574C4E2

P2860

Q36976659-0F982501-B46F-4843-B8D8-D82C02D232F9

Q36976659-1962E9F6-30A5-498D-9469-D1DE7CF966E6

Q36976659-1CE0D8E9-9603-4FAA-ADF7-82CD3E123A35

Q36976659-25255EFE-E0C4-41FD-B86C-C4F5B74AD289

Q36976659-2F2D8A98-5147-49D9-ADCA-D2940AA36B38

Q36976659-3073FD90-B0DB-4876-ABDA-BCC7529C3FDF

Q36976659-423ED427-C7FE-4718-AC4E-2E21E0C97BA2

Q36976659-4F965051-5BEF-49BE-8318-21AE97A43514

Q36976659-5BF3703F-FB23-4C24-B885-3653266FAC5A

Q36976659-5D30879D-1371-42E7-A17B-EC82A835FCD9

P304

Q36976659-586777C7-244F-47C0-9D48-92AA3890B114

P31

Q36976659-A20F781A-4811-45F5-83B4-88E6308C8310

P356

Q36976659-CCE721DD-452C-49D9-97B4-56A3156E2707

P407

Q36976659-6B5C894D-20B9-40EA-8A8C-343C3A0DC657

P433

Q36976659-5A8E349D-28C0-40B3-906A-123D166E5D38

P478

Q36976659-97246D58-A05E-4AC9-B371-345D489D5DA6

P577

Q36976659-4C5E07F5-2B1B-4A64-8B90-62161B41E24F

P5875

Q36976659-A8F598E5-AEEB-4747-8AC1-F8F241D5E3C6

P698

Q36976659-98810F09-1C0C-48BC-B5A0-675261C30C70

P932

Q36976659-9343D147-5966-4331-A4B9-4FBF8CF2AF87

P356

PNAS.0805098105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Highly potent, fully recombina ...... eering a low-cost microbicide.

@en

P2093

Astrid Melotti

http://www.w3.org/2001/XMLSchema#string

Donald Mosier

http://www.w3.org/2001/XMLSchema#string

Fabrice Cerini

http://www.w3.org/2001/XMLSchema#string

Gabriel Kuenzi

http://www.w3.org/2001/XMLSchema#string

Guy Gorochov

http://www.w3.org/2001/XMLSchema#string

Hubert Gaertner

http://www.w3.org/2001/XMLSchema#string

Irène Rossitto-Borlat

http://www.w3.org/2001/XMLSchema#string

Janelle Salkowitz

http://www.w3.org/2001/XMLSchema#string

Jean-Michel Escola

http://www.w3.org/2001/XMLSchema#string

Oliver Hartley

http://www.w3.org/2001/XMLSchema#string

P2860

Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling

Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies.

Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.

Engineering chemokines to develop optimized HIV inhibitors.

Which topical microbicides for blocking HIV-1 transmission will work in the real world?

Genetic subtype-independent inhibition of human immunodeficiency virus type 1 replication by CC and CXC chemokines.

Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.

Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus.

Dancing to the tune of chemokines.

Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES

P304

17706-17711

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0805098105

http://www.w3.org/2001/XMLSchema#string

P407

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23469203

http://www.w3.org/2001/XMLSchema#string

P698

19004761

http://www.w3.org/2001/XMLSchema#string

P932

2584686

http://www.w3.org/2001/XMLSchema#string